Total Payments
$89,344
2023 Payments
$4,562
Companies
11
Transactions
48
Medicare Patients
454
Medicare Billing
$92,282
Payment Breakdown by Category
Consulting$83,622 (93.6%)
Research$3,010 (3.4%)
Travel$1,999 (2.2%)
Food & Beverage$712.64 (0.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $83,622 | 24 | 93.6% |
| Unspecified | $3,010 | 2 | 3.4% |
| Travel and Lodging | $1,999 | 7 | 2.2% |
| Food and Beverage | $712.64 | 15 | 0.8% |
Payments by Type
General
$86,333
46 transactions
Research
$3,010
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $30,198 | 14 | $0 (2023) |
| Janssen Research & Development, LLC | $28,850 | 12 | $0 (2022) |
| Janssen Global Services, LLC | $8,740 | 3 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $7,115 | 7 | $0 (2019) |
| SANOFI US SERVICES INC. | $5,214 | 2 | $0 (2020) |
| Amgen Inc. | $4,023 | 3 | $0 (2018) |
| Celgene Corporation | $2,866 | 1 | $0 (2018) |
| Genentech, Inc. | $1,980 | 1 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $209.70 | 3 | $0 (2019) |
| Seagen Inc. | $133.94 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $4,562 | 2 | SANOFI-AVENTIS U.S. LLC ($4,562) |
| 2022 | $183.29 | 2 | Seagen Inc. ($133.94) |
| 2021 | $4,780 | 1 | SANOFI-AVENTIS U.S. LLC ($4,780) |
| 2020 | $21,148 | 8 | Janssen Global Services, LLC ($8,740) |
| 2019 | $38,400 | 10 | Janssen Research & Development, LLC ($26,800) |
| 2018 | $20,124 | 23 | SANOFI-AVENTIS U.S. LLC ($6,952) |
| 2017 | $146.70 | 2 | E.R. Squibb & Sons, L.L.C. ($146.70) |
All Payment Transactions
48 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/08/2023 | SANOFI-AVENTIS U.S. LLC | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $2,389.75 | General |
| Category: Oncology | ||||||
| 12/08/2023 | SANOFI-AVENTIS U.S. LLC | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $2,172.50 | General |
| Category: Oncology | ||||||
| 09/23/2022 | Seagen Inc. | — | Food and Beverage | In-kind items and services | $133.94 | General |
| 09/05/2022 | Janssen Research & Development, LLC | DARZALEX (Drug) | Food and Beverage | In-kind items and services | $49.35 | General |
| Category: Oncology | ||||||
| 07/28/2021 | SANOFI-AVENTIS U.S. LLC | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $4,779.50 | General |
| Category: Oncology | ||||||
| 12/14/2020 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $1,860.00 | General |
| 11/27/2020 | SANOFI US SERVICES INC. | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $3,476.00 | General |
| Category: Oncology | ||||||
| 11/27/2020 | SANOFI US SERVICES INC. | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $1,738.00 | General |
| Category: Oncology | ||||||
| 11/20/2020 | Genentech, Inc. | VENCLEXTA (Biological) | Consulting Fee | Cash or cash equivalent | $1,980.00 | General |
| Category: BioOncology | ||||||
| 11/11/2020 | Janssen Global Services, LLC | DARZALEX (Biological) | Consulting Fee | Cash or cash equivalent | $3,780.00 | General |
| Category: Oncology | ||||||
| 10/23/2020 | Janssen Global Services, LLC | DARZALEX (Biological) | Consulting Fee | Cash or cash equivalent | $3,100.00 | General |
| Category: Oncology | ||||||
| 05/11/2020 | SANOFI-AVENTIS U.S. LLC | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $3,476.00 | General |
| Category: Oncology | ||||||
| 05/11/2020 | SANOFI-AVENTIS U.S. LLC | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $1,738.00 | General |
| Category: Oncology | ||||||
| 10/30/2019 | SANOFI-AVENTIS U.S. LLC | ISATUXIMAB (Drug) | Consulting Fee | Cash or cash equivalent | $3,476.00 | General |
| 10/30/2019 | SANOFI-AVENTIS U.S. LLC | ISATUXIMAB (Drug) | Consulting Fee | Cash or cash equivalent | $1,738.00 | General |
| 09/16/2019 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Consulting Fee | Cash or cash equivalent | $2,640.00 | General |
| Category: Oncology | ||||||
| 09/16/2019 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $37.14 | General |
| Category: Oncology | ||||||
| 09/16/2019 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Travel and Lodging | Cash or cash equivalent | $25.00 | General |
| Category: Oncology | ||||||
| 06/12/2019 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $63.00 | General |
| 04/29/2019 | SANOFI-AVENTIS U.S. LLC | ISATUXIMAB (Drug) | Consulting Fee | Cash or cash equivalent | $1,738.00 | General |
| 04/29/2019 | SANOFI-AVENTIS U.S. LLC | ISATUXIMAB (Drug) | Consulting Fee | Cash or cash equivalent | $1,738.00 | General |
| 04/16/2019 | Janssen Research & Development, LLC | DARZALEX (Drug) | Consulting Fee | Cash or cash equivalent | $26,800.00 | General |
| Category: Oncology | ||||||
| 03/22/2019 | Takeda Pharmaceuticals U.S.A., Inc. | Ninlaro (Drug) | — | Cash or cash equivalent | $144.38 | Research |
| Study: Study of Dexamethasone Plus IXAZOMIB MLN9708 or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain AL Amyloidosis • Category: Oncology | ||||||
| 12/24/2018 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.33 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/12/2018 | SANOFI-AVENTIS U.S. LLC | ISATUXIMAB (Drug) | Consulting Fee | Cash or cash equivalent | $869.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RV-MM-PI-0385 - A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma | Celgene Corporation | $2,866 | 1 |
| Study of Dexamethasone Plus IXAZOMIB MLN9708 or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain AL Amyloidosis | Takeda Pharmaceuticals U.S.A., Inc. | $144.38 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 138 | 243 | $112,938 | $26,541 |
| 2022 | 3 | 133 | 251 | $118,092 | $28,058 |
| 2021 | 3 | 116 | 207 | $92,539 | $22,767 |
| 2020 | 3 | 67 | 167 | $61,646 | $14,916 |
Total Patients
454
Total Services
868
Medicare Billing
$92,282
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 66 | 115 | $60,939 | $13,117 | 21.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 18 | 74 | $22,138 | $6,914 | 31.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 35 | 35 | $22,621 | $5,009 | 22.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 19 | 19 | $7,240 | $1,502 | 20.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 89 | 145 | $75,189 | $16,841 | 22.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 81 | $26,468 | $7,284 | 27.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 25 | 25 | $16,435 | $3,932 | 23.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 74 | 98 | $47,040 | $11,458 | 24.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 18 | 85 | $29,155 | $7,598 | 26.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 24 | 24 | $16,344 | $3,711 | 22.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 16 | 69 | $22,275 | $6,263 | 28.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 39 | 60 | $27,097 | $5,402 | 19.9% |
| 36514 | Mechanical separation of plasma from opening blood | Facility | 2020 | 12 | 38 | $12,274 | $3,251 | 26.5% |
About Dr. Raymond Comenzo, MD
Dr. Raymond Comenzo, MD is a Hematology & Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1750352787.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Raymond Comenzo, MD has received a total of $89,344 in payments from pharmaceutical and medical device companies, with $4,562 received in 2023. These payments were reported across 48 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($83,622).
As a Medicare-enrolled provider, Comenzo has provided services to 454 Medicare beneficiaries, totaling 868 services with total Medicare billing of $92,282. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology
- Location Boston, MA
- Active Since 01/28/2006
- Last Updated 03/19/2013
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1750352787
Products in Payments
- DARZALEX (Drug) $28,850
- SARCLISA (Biological) $19,770
- ISATUXIMAB (Drug) $15,642
- NINLARO (Drug) $6,971
- DARZALEX (Biological) $6,880
- Kyprolis (Biological) $3,850
- Revlimid (Drug) $2,866
- VENCLEXTA (Biological) $1,980
- Ninlaro (Drug) $144.38
- XIFAXAN (Drug) $14.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Boston
Dr. Julio Hajdenberg, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Eric Jacobsen, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Paul Richardson, Md, MD
Hematology & Oncology — Payments: $920,265
Hematology & Oncology $920,265
Matthew Davids, M.d, M.D
Hematology & Oncology — Payments: $808,362
Hematology & Oncology $808,362
David Avigan, M.d, M.D
Hematology & Oncology — Payments: $679,225
Hematology & Oncology $679,225
Anthony Letai, Md, MD
Hematology & Oncology — Payments: $569,795
Hematology & Oncology $569,795